Publications by authors named "A Minchom"

Claim this Profile
F
First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors.
A Minchom, O Lindén, D G Knapen, R Hassan, F I Lin

ESMO Open· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial.
Susana Banerjee, Matthew G Krebs, Alastair Greystoke, Alvaro Ingles Garces, Vicky Sanchez Perez, Anna Minchom

Nat Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.
Mariam Alexander, Ying Cheng, Se-Hoon Lee, Antonio Passaro, Alexander I Spira, Anna R Minchom

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors.
Jia Liu, Anna R Minchom, Alastair Greystoke, Thomas R J Evans, Debashis Sarker

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-related adverse events of antibody drug-conjugates in clinical trials.
Harold Nathan Tan, Marta Ascanio Morcillo, Juanita Lopez, Anna Minchom, Adam Sharp

J Hematol Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis